Kuvan

Sapropterin dihydrochloride, the active ingredient in Kuvan, is a synthetic tetrahydrobiopterin (BH4) presented as a tablet for oral use. It is employed to treat phenylketonuria in patients who demonstrate responsiveness to BH4 therapy, helping to lower elevated blood phenylalanine concentrations. By supplying the necessary cofactor for phenylalanine hydroxylase, it enhances conversion of phenylalanine to tyrosine, contributing to metabolic control.

GNH USA supplies Kuvan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide.

Kuvan is used in the management of disorders related to phenylalanine metabolism.

Phenylketonuria (BH4‑responsive): reduces blood phenylalanine levels, allowing a less restrictive diet. Hyperphenylalaninemia: lowers elevated phenylalanine concentrations in patients with this metabolic condition. Dietary management of PKU: enables increased natural protein intake when combined with dietary therapy.

Adverse reactions reported with Kuvan are generally mild, but serious events can occur.

Common Side Effects: - Headache - Nausea - Vomiting - Abdominal pain - Fatigue

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity reactions - Thrombocytopenia - Significant elevation of liver enzymes

When prescribing Kuvan, clinicians should observe several precautionary measures to ensure safe use.

Assess BH4 responsiveness: confirm patient’s responsiveness through a trial before long‑term therapy. Monitor phenylalanine levels: regularly check blood phenylalanine concentrations to adjust dosage. Adjust dietary intake: coordinate with dietitians to modify phenylalanine intake as needed. Use caution in renal impairment: evaluate kidney function prior to initiation. Avoid in patients with known hypersensitivity to sapropterin or any tablet excipients. Store at ambient temperature: keep tablets in the original container, protect from moisture and heat.

Kuvan may interact with other substances that influence phenylalanine metabolism or drug absorption.

Major Interactions (Avoid): - Phenylalanine supplements: can negate the drug’s effect on lowering phenylalanine levels. - High‑dose vitamin C: may increase urinary excretion of sapropterin, reducing efficacy.

Moderate Interactions (Monitor Closely): - Antiepileptic drugs (e.g., carbamazepine, phenytoin): may alter phenylalanine metabolism. - Oral contraceptives: potential to affect phenylalanine concentrations. - Vitamin B6 (pyridoxine) supplementation: may interfere with BH4 pathways. - Protein‑rich meals: can affect absorption and plasma levels of sapropterin.